ストックスクリーナーアプリを入手
157.69
2.38%
3.67
アフターアワーズ：
157.80
0.11
+0.07%
前日終値:
$154.02
開ける：
$155
24時間の取引高:
222.51K
Relative Volume:
1.19
時価総額：
$6.32B
収益：
-
当期純損益:
$-77.61M
株価収益率:
-68.62
EPS:
-2.2979
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+2.41%
1か月 パフォーマンス:
+10.00%
6か月 パフォーマンス:
-3.96%
1年 パフォーマンス:
+168.96%
1日の値動き範囲:
$154.25
$158.90
1週間の範囲:
$140.99
$158.90
52週間の値動き範囲:
$58.77
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
157.69 | 6.17B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-26 | 開始されました | BofA Securities | Buy |
| 2026-01-06 | 開始されました | Morgan Stanley | Overweight |
| 2025-12-02 | アップグレード | Mizuho | Neutral → Outperform |
| 2025-11-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-11-20 | 開始されました | Mizuho | Neutral |
| 2023-12-14 | 開始されました | Maxim Group | Buy |
| 2023-07-28 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-07-26 | 開始されました | SVB Securities | Outperform |
| 2022-08-01 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-01 | 開始されました | The Benchmark Company | Buy |
すべてを表示
Belite Bio Inc Adr (BLTE) 最新ニュース
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences - markets.businessinsider.com
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - The Manila Times
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium - GlobeNewswire Inc.
Responsive Playbooks and the BLTE Inflection - Stock Traders Daily
Price to earnings forward of Belite Bio, Inc. ADR – FWB:D01 - TradingView
BLTE Stock Price, Quote & Chart - ChartMill
Belite Bio, Inc. ADR Actuals & Estimates (NASDAQ:BLTE) - TradingView
Understanding the Setup: (BLTE) and Scalable Risk - Stock Traders Daily
Belite Bio (BLTE) After Its FDA Filing, Does The Stock Still Look Undervalued - Sahm
H.C. Wainwright Keeps Their Buy Rating on RegenXBio (RGNX) - The Globe and Mail
Top Executive Makes Major Move With Belite Bio Stock Sale - TipRanks
Belite Bio CMO Scholl sells over $1.45m in company shares - Investing.com Nigeria
Form 4 Belite Bio Inc ADR For: 22 June By Investing.com - Investing.com South Africa
Bioptima Ltd. tied to Belite Bio (BLTE) CMO sells 10,000 ADSs in open market - Stock Titan
Why Belite Bio (BLTE) Is Up 5.8% After Completing FDA NDA Submission For Tinlarebant - Sahm
BLTE News | BELITE BIO INCADR (NASDAQ:BLTE) - ChartMill
Dr. Hendrick Scholl sells 10,000 ADS as Form 144 filed (NASDAQ: BLTE) - Stock Titan
Belite Bio Soars After Key FDA Filing Milestone - TipRanks
Belite Bio CMO Scholl sells $1.4m shares from $137.61 to $145.02 - Investing.com India
Belite Bio (BLTE) CMO-affiliated entity sells 10,000 ADS, retains 32,946 - Stock Titan
BLTE (NASDAQ: BLTE) files Rule 144 notice to sell 10,000 ADS under vested RSUs - Stock Titan
Belite Bio stock price target maintained at $200 by H.C. Wainwright on NDA completion - Investing.com Nigeria
Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Climb Bio (CLYM) and Intuitive Surgical (ISRG) - The Globe and Mail
BLTE Reiterated by HC Wainwright & Co. -- Price Target Maintained at $200 - GuruFocus
The Technical Signals Behind (BLTE) That Institutions Follow - Stock Traders Daily
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 - The Manila Times
Belite Bio (NASDAQ: BLTE) completes FDA NDA submission for tinlarebant in Stargardt disease - Stock Titan
Belite Bio Shares Surge on Drug Filing Hopes - TipRanks
Precision Trading with Belite Bio Inc (BLTE) Risk Zones - Stock Traders Daily
Belite Bio to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference - markets.businessinsider.com
Why Belite Bio Stock Is Sinking Again Today - TipRanks
Belite Bio Stock Tumbles as Wall Street Cools - TipRanks
Belite Bio Stock Slumps On Mounting Doubts - TipRanks
Belite Bio (BLTE) Hovers Near Resistance as Price Action Remains MutedBear Flag - The Legal Advocate
H.C. Wainwright Sticks to Their Buy Rating for Opko Health (OPK) - The Globe and Mail
BLTE - Finviz
Mizuho lowers Belite Bio stock price target to $215 on valuation - Investing.com UK
Mizuho lowers Belite Bio stock price target to $215 on valuation By Investing.com - Investing.com South Africa
Mizuho Adjusts Price Target on Belite Bio to $215 From $223, Maintains Outperform Rating - Moomoo
Technical Reactions to BLTE Trends in Macro Strategies - Stock Traders Daily
Belite Bio shares rise after first-quarter earnings outperform expectations (BLTE) - MSN
Benchmark reiterates Belite Bio stock rating on drug development progress By Investing.com - Investing.com Nigeria
Benchmark reiterates Belite Bio stock rating on drug development progress - Investing.com
Analysts Are Bullish on Top Healthcare Stocks: Belite Bio, Inc. ADR (BLTE), Centene (CNC) - The Globe and Mail
Belite Bio Inc Adr (BLTE) 財務データ
収益
当期純利益
現金流量
EPS
1.17%
2.48%
大文字化:
|
ボリューム (24 時間):